mRNA |
avrainvillamide |
CTRPv2 |
pan-cancer |
AAC |
-0.013 |
0.8 |
mRNA |
CIL41 |
CTRPv2 |
pan-cancer |
AAC |
-0.016 |
0.8 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.01 |
0.8 |
mRNA |
bafilomycin A1 |
CTRPv2 |
pan-cancer |
AAC |
0.05 |
0.8 |
mRNA |
erlotinib:PLX-4032 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.012 |
0.8 |
mRNA |
AT13387 |
CTRPv2 |
pan-cancer |
AAC |
0.014 |
0.8 |
mRNA |
dacarbazine |
CTRPv2 |
pan-cancer |
AAC |
-0.0095 |
0.8 |
mRNA |
ML050 |
CTRPv2 |
pan-cancer |
AAC |
-0.011 |
0.8 |
mRNA |
Crizotinib |
CTRPv2 |
pan-cancer |
AAC |
-0.0095 |
0.8 |
mRNA |
GSK-J4 |
CTRPv2 |
pan-cancer |
AAC |
-0.036 |
0.8 |